ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. grew its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 6.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 89,961 shares of the specialty pharmaceutical company’s stock after purchasing an additional 5,829 shares during the quarter. Principal Financial Group Inc.’s holdings in ANI Pharmaceuticals were worth $5,367,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ANIP. Innealta Capital LLC acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $65,000. Ridgewood Investments LLC acquired a new position in ANI Pharmaceuticals during the second quarter worth $85,000. SG Americas Securities LLC purchased a new stake in ANI Pharmaceuticals in the 1st quarter valued at $106,000. XTX Topco Ltd acquired a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth $207,000. Finally, O Shaughnessy Asset Management LLC purchased a new position in shares of ANI Pharmaceuticals during the 1st quarter worth $218,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $55.10 on Thursday. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81. The stock has a market capitalization of $1.16 billion, a PE ratio of -100.18 and a beta of 0.71. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The stock has a 50-day simple moving average of $58.35 and a 200-day simple moving average of $61.07.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. During the same period last year, the firm earned $1.05 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 12.5% on a year-over-year basis. On average, analysts predict that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ANIP. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Truist Financial upped their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. Piper Sandler started coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 target price for the company. Raymond James upped their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. Finally, HC Wainwright reissued a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $77.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.